Proactively manage your pharmacy inventory
Anticipate generic drug launch
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Imidazodiazepines and processes therefor|
|Abstract:||Novel imidazobenzodiazepines and their analogs are useful as anticonvulsants, muscle relaxant, anxiolytic and sedative agents. Preferred compounds of this class belong to the imidazo[1,5-a][1,4] diazepine series which may have a very wide variety of organic substituents. An especially preferred genus included with the purview of the invention encompasses a compound of the formula ##STR1## wherein R.sub.1 is hydrogen and lower alkyl, preferably methyl; R.sub.3 and R.sub.5 are hydrogen; R.sub.4 is hydrogen, nitro or halogen, most preferably, chlorine, and in a most preferred embodiment when positioned on the fused benzo portion of the imidazobenzodiazepine is in the 8-position thereof; R.sub.6 is phenyl or halo, nitro, or lower alkyl-substituted phenyl, preferably, halo, with fluorine being the preferred halogen, the substituted fluoro being positioned in the 2-position of the phenyl moiety; and R.sub.2 is hydrogen and lower alkyl.|
|Inventor(s):||Walser; Armin (West Caldwell, NJ), Fryer; Rodney I. (North Caldwell, NJ)|
|Assignee:||Hoffmann-La Roche Inc. (Nutley, NJ)|
|Filing Date:||Mar 12, 1981|
|Claims:||1. A compound of the formula ##STR85## wherein A is ##STR86## R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, ##STR87## phenyl, C.sub.1 to C.sub.7 alkoxyl lower alkyl, halo lower alkyl, amino lower alkyl, mono or di-C.sub.1 to C.sub.7 alkyl or phenyl, chlorophenyl or tolyl substituted amino lower alkyl, pyridyl, benzyl and the group R.sup.65 CO wherein R.sup.65 is hydrogen or lower alkyl; R.sub.2 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, C.sub.1 to C.sup.7 acyloxy lower alkyl, C.sub.1 to C.sub.7 alkoxy lower alkyl, halo lower alkyl, cyano, cyano lower alkyl, mono- or di-C.sub.1 to C.sub.7 alkyl or phenyl, chlorophenyl or tolyl substituted amino lower alkyl, amino lower alkyl, mono- or di-C.sub.1 to C.sub.7 alkyl or phenyl, chlorophenyl or tolyl substituted amino, the group COOR where R is hydrogen or lower alkyl, the group RCO where R is hydrogen or lower alkyl, or the group R-C.dbd.N-R' wherein R' is hydrogen, lower alkyl, hydroxy, phenyl, alkoxy, amino, mono or di-alkylamino and arylamino and R is hydrogen or lower alkyl, the group ##STR88## (where R.sup.85, R.sup.86 are hydrogen, lower alkyl, aryl, hydroxy lower alkyl, lower alkenyl, or together R.sup.85 and R.sup.86 with the nitrogen atom may form a part of a 5- or 6-membered heterocyclic ring selected from the group consisting of morpholino piperazino, piperidino and pyrrolidino and the group (CH.sub.2).sub.n NR.sup.95 R.sup.96 where R.sup.95 and R.sup.96 are hydrogen, lower alkyl, hydroxy lower alkyl, lower alkenyl, aryl or together R.sup.95 and R.sup.96 with the nitrogen atom form a part of a 5- or 6-membered heterocyclic ring selected from the group consisting of morpholino, piperazino, piperidino and pyrrolidino) or the group ##STR89## where R.sup.10, R.sup.11, R.sup.12 are hydrogen, lower alkyl or the group (CH.sub.2).sub.n NR.sup.13 R.sup.14 where n is 1 to 4 and R.sup.13, R.sup.14 are hydrogen or lower alkyl with the limitation that where R.sup.10, R.sup.11 or R.sup.12 is (CH.sub.2).sub.n NR.sup.13 R.sup.14 then the remaining substituents are hydrogen or lower alkyl; R.sub.3 is selected from the group consisting of hydrogen or lower alkyl; R.sub.5 is hydrogen; R.sub.6 is selected from the group consisting of phenyl, mono-halo or mono-nitro substituted phenyl, di-halo or halo-nitro substituted phenyl, pyridyl and mono-halo or mono-nitro substituted pyridyl R.sup.20 is C.sub.1 to C.sub.6 or hydrogen; and ##STR90## and the pharmaceutically acceptable salts thereof. |
2. A compound of the formula: 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-imidazo[1,5-a]thieno[3,2-f][1,4]di azepine-3-carboxamide.
3. A compound of the formula: 8-chloro-6-(2-chlorophenyl)-1,N,N-trimethyl-4H-imidazo[1,5-a]thieno[3,2-f] [1,4]diazepine-3-carboxamide.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.